Chilblains in Southern California: two case reports and a review of the literature

Table 1 Summary of laboratory data for cases 1 and 2

Laboratory evaluation	Normal range	Case 1	Case 2
Antinuclear Ab	< 1:40 titer	1:160	<1:40
Anti- dsDNA Ab EIA	<200IU/mL	<200	<200
Erythrocyte sedimentation rate, Westergren	0–10mm/hour	5	5
C3	71–141mg/dL	133	120
C4	12–34mg/dL	49	22
Rheumatoid factor	<25IU/mL	<10	<10
C-reactive protein	<0.8mg/dL	0.3	0.3
C-ANCA	<1:20 titer	<1:20	<1:20
P-ANCA	<1:20 titer	<1:20	<1:20
Proteinase-3 Ab	<21U	<21	<21
Myeloperoxidase Ab	<21U	<21	<21
Cardiolipin IgG	<15GPL	<15	<15
Cardiolipin IgM	<12.5MPL	<12.5	<12.5
Cardiolipin IgA	<12APL	<12	<12
Beta-2-Glycoprotein IgG	≤20SGU	<9	<9
Beta-2-Glycoprotein IgM	≤20SMU	<9	<9
Beta-2-Glycoprotein IgA	≤20SAU	<9	<9
Anti- SM Ab	<20U	<20	<20
Anti- RNP AB	<20U	<20	<20
Anti- SSA Ab	<20U	<20	<20
Anti- SSB Ab	<20U	<20	<20
CH50, Total complement	60–144 CAE units	154	96
Immunofixation interpretation	Normal	Normal	Normal
Cryocrit	Negative	Negative	Negative
Hepatitis B surface Ab quantitative	<10IU/L	<10	<10
Hepatitis B surface antigen	Negative	Negative	Negative
Hepatitis C Ab	Negative	Negative	Negative
Rapid plasma reagin (RPR)	Nonreactive	Nonreactive	Nonreactive

Abbreviations: Ab, antibody; Anti-dsDNA Ab EIA, anti-double-stranded DNA antibody by enzyme-linked immunosolvent assay; Anti-RNP Ab, antiribonucleoprotein antibodies; Anti-SM Ab, anti-Smith antibodies; Anti-SSA, anti-Sjögren’s Syndrome A antibody; Anti-SSB, anti-Sjögren’s Syndrome B antibody; C3, complement component 3; C4, complement component 4; C-ANCA, cytoplasmic antineutrophil cytoplasmic antibodies; CH50, 50% hemolytic complement; Cryocrit, percent of packed cryoglobulins; Ig, immunoglobulin; P-ANCA, perinuclear antineutrophil cytoplasmic antibodies. Bold values are abnormal.

ISSN: 1752-1947